Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).
Clinical Pearls
Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial looking at overcoming mTOR resistance in renal cell carcinoma (RCC).
This study represents the first step in a long process: testing the hypothesis that HDAC inhibition can overcome resistance to mTOR inhibition
Two patients treated with prior mTOR inhibitors progressed and then did well when treated with the combination of ridaforolimus and vorinostat
Ridaforolimus 20 mg once daily plus vorinostat 100 mg once daily will be tested in a larger trial in patients who had both prior mTOR inhibitors and those who did not
